Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00840047 · ClinicalTrials.gov registry record · Phase 2

Methionine PET/CT Studies In Patients With Cancer

A Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital.

Active
Registry status
Phase 2
Development phase
503
Enrollment target
1
Study location

NCT00840047 is a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 503 participants, above the 147-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (242% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00840047, a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
503 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid. It is crucial for the formation of proteins. When labeled with carbon-11 (C-11), a radioactive isotope of the naturally occurring carbon-12, the distribution of methionine can be determined noninvasively using a PET (positron emission tomography) camera. C-11 methionine (MET) has been shown valuable in the monitoring of a large number of neoplasms. Since C-11 has a short half life (20 minutes), MET must be produced in a facility very close to its intended use. Thus, it is not widely available and is produced only at select institutions with access to a cyclotron and PET chemistry facility. With the new availability of short lived tracers produced by its PET chemistry unit, St. Jude Children's Research Hospital (St. Jude) is one of only a few facilities with the capabilities and interests to evaluate the utility of PET scanning in the detection of tumors, evaluation of response to therapy, and distinction of residual tumor from scar tissue in patients who have completed therapy. The investigators propose to examine the biodistribution of MET in patients with malignant solid neoplasms, with emphasis on central nervous system (CNS) tumors and sarcomas. This project introduces a new diagnostic test for the noninvasive evaluation of neoplasms in pediatric oncology. Although not the primary purpose of this proposal, the investigators anticipate that MET studies will provide useful clinical information for the management of patients with malignant neoplasms.

Interventions

  • DRUG Methionine

Study Locations (1)

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Trial Details

FieldValue
Enrollment Target 503 participants
Start Date 2009-07-20
Est. Completion 2027-07-27
Phase Phase 2

What the Registry Record Tells You About NCT00840047

The ClinicalTrials.gov registry entry for NCT00840047 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 503 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 147-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (242% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Methionine is the first listed.

NCT00840047 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00840047 about?

NCT00840047 is a clinical study titled "Methionine PET/CT Studies In Patients With Cancer". The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid. It is crucial for the formation of proteins. When labeled with carbon-11 (C-11), a radio...

What is the current status of trial NCT00840047?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 503 participants. The study started on 2009-07-20. Estimated completion is 2027-07-27.

What conditions does trial NCT00840047 study?

This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Medulloblastoma, Ewing Sarcoma, Ependymoma.

What interventions are being tested in trial NCT00840047?

The interventions under investigation include: Methionine (DRUG).

Who is sponsoring clinical trial NCT00840047?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00840047 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.